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Metastasis is the most common intraocular neoplasm
mostly localizing to the choroid.1 Ocular metastasis occurs
in 2–9% of all malignancies, of which 47–81% are from breast
primaries and 9–23% are from lung primaries.2 69–88% of
intraocular metastases localize to the choroid, with the major-
ity of lung metastatic lesions being unifocal.1,3 Metastatic
ocular lesions may be clinically silent, with only an estimated
12% involving the macula.3 At the time of ocular diagnosis,
34% have an unknown primary.3
The World Health Organization estimated that 12.7 million
new cases of cancer occurred worldwide in 2008.4 Lung can-
cer is the most frequent malignant neoplasm, accounting for
16.5% of all new malignancy diagnoses in men and 8.5% inwomen worldwide.4 The incidence of symptomatic ocular
lung metastasis is between 1% and 7%.1 Due to the reduction
in smoking amongst the population, relatively more individu-
als are developing non-small cell lung carcinoma (NSCLC),
particularly adenocarcinoma.5 Lung adenocarcinoma can
arise in never-smokers, and such patients are more likely to
have an activating mutation of the epidermal growth factor
receptor (EGFR) pathway or echinoderm microtubule associ-
ated protein and anaplastic lymphoma kinase (EML4-ALK)
gene translocation.5 Much progress has been made in the
understanding and identification of the cellular mechanism
underlying tumorigenesis and progression. These mecha-
nisms primarily involve a multitude of pathways including
the well recognized EGFR and K-ras anti-apoptotic path-
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sented initially as a symptomatic ocular metastasis. We pro-
vide an in-depth discussion of ocular pulmonary metastases
and management options.Case report
A 44-year-old, never-smoker, otherwise healthy man pre-
sented with 3-days of a superior visual field defect in his left
eye (OS) with a visual acuity of 20/25. Dilated funduscopic
examination disclosed an 11  10 mm amelanotic choroidal
mass near the macula OS (Fig. 1A). Ultrasonographic exami-
nation showed a dome-shaped lesion measuring 3.9 mm in
height with high internal reflectivity. Diagnostic imaging re-
vealed a 55  40 mm left lower lobe (LLL) lung lesion
(Fig. 1B), which on fine needle aspirate biopsy (FNAB) wasFigure 1. (A) Left fundus of a choroidal metastasis showed a large dome-sha
lower lobe lesion was revealed by lateral chest X-ray. (C–E) Using serial MRI s
initially effective at reducing tumor size (arrows) (C, pre-treatment; D, post
enlarged (E, arrow) causing significant ocular pain. (F) Cross sections of the
posterior aspect of the globe measuring 20 mm in base and 9 mm in height
margin of the surgical transection (hematoxylin-eosin, 25).identified as an adenocarcinoma. Genetic testing was nega-
tive for EGFR mutation. Biopsy specimens of the mediastinal
lymph nodes were positive for metastatic disease and he was
staged at T2, N2, and M1.7 A magnetic resonance imaging
(MRI) scan of the brain detected an intraocular lesion measur-
ing 10  4 mm (Fig. 1C).
During the 8 weeks’ investigative process, the ocular lesion
continued to enlarge and the patient experienced increasing
pain and decreasing vision. Nine weeks after his initial presen-
tation, he received targeted radiation therapy to the posterior
pole OS (30 Gy in 10 fractions). While the ocular pain and
tumor size diminished, the patient’s visual acuity did not im-
prove (Fig. 1D). He also was treated aggressively with chemo-
therapy (cisplatin and vinorelbine) and radiotherapy (60 Gy in
20 fractions over the course of 7 weeks) targeted to the
primary lesion 10 weeks following his initial presentation. He
responded well with a marked reduction in the LLL tumor sizeped amelanotic tumor with retinal pigment epithelium clumping. (B) Left
tudies, it was noted that combined radiotherapy and chemotherapy were
-treatment). However, over the subsequent 1.5 years, tumor size slowly
enucleated left globe revealed an amelanotic tumor mass (CA) in the
. (G) The tumor cells invaded through the lamina cribrosa (arrow) to the
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graphic (CT) restaging. While the ocular tumor mass was sta-
ble, the patient’s visual deficits continued to worsen. Eight
months after his initial presentation, he had no light percep-
tion with worsening ocular pain. Over the next year, follow-
up studies showed progressive metastatic disease with new
lesions identified in the liver, cerebellum, and multiple small
nodules in the left lung base. Also, the mediastinal nodes en-
larged and his chronic cough progressed to hemoptysis. The
patient began to experience pain on extraocular movement
and a repeated MRI showed progression of the OS lesion
(Fig. 1E). He underwent enucleation for palliative pain man-
agement 14 months after being diagnosed with non-small cell
lung carcinoma (Fig. 1F). Post-operatively, ocular pain levels
improved. His systemic disease continued to progress, with
an enlargement of the hepatic metastasis and the multiple
lung nodules. Due to disease progression, he was treated with
a second course of chemotherapy on a clinical trial consisting
of docetaxel. He tolerated this treatment well and no disease-
related symptoms aside from slight worsening orbital discom-
fort were observed.Figure 2. (A–E) The ocular tumor formed gland-like structure (A, hematoxylin-
and a displaced crescent shaped nucleus (B, arrows, hematoxylin-eosin, 400
acid-Schiff, 400; D, arrows, colloidal iron, 400; E, arrow, mucicarmine, 40
tumor cells with the cytoplasm filled with a predominantly radiolucent vacu
crescent cap (arrow) in a signet ring configuration (original magnification  2
eosin, 400) and mediastinal lymph node (H, hematoxylin-eosin, 400) demoGross pathological examination (Fig. 1F) disclosed a pos-
terior choroidal tumor measuring 20 mm in maximal base
and 9 mm in maximal height. On histopathological examina-
tion, the tumor formed nests, cords, and islands surrounded
by fibrovascular stroma and displayed a perivascular growth
pattern with numerous cholesterol clefts. The tumor cells
invaded the anterior-posterior section of the optic nerve
extending to its cut edge (Fig. 1G). The tumor cells had pleo-
morphic nuclei, prominent nucleoli, abundant cytoplasm with
well-demarcated borders and neoplastic atypical mitoses
were noted. The tumor formed occasional gland-like struc-
tures (Fig. 2A) and contained cells with abundant vacuolated
cytoplasm with well demarcated cell boarders imparting a
signet ring appearance (Fig. 2B), which stained strongly posi-
tive for mucus production (Fig. 2C–F). The prior FNAB and
mediastinal lymph node biopsies showed similar cytomor-
phological features (Fig. 2G and H). The tumor extended into
and destroyed the overlying degenerated, necrotic retina. It
also invaded the adjacent sclera to 25% of its depth, but
there was no evidence of extrascleral extension or invasion
into the subarachnoid space.eosin, 100) with numerous signet ring cells with a vacuolated cytoplasm
) and stained strongly positive for mucus production (C, arrows, periodic
0). (F) Transmission electron microscopy of the ocular specimen identified
olated fibrillo-granular material with displacement of the nucleus into a
500). (G and H) Reassessment of the lung nodule FNAB (G, hematoxylin-
nstrated similar signet ring cells (arrows).
Figure 3. (A–C) Immunohistochemical staining for ALK gene rearrangement using anti-ALK antibody (5A4) showed extensive positivity in all three biopsy
specimens (A, lung nodule FNAB, 100; B, mediastinal lymph node, 100; C, choroidal metastasis, 100). (D) FISH analysis of the choroidal metastatic
lesion is positive for ALK translocation as indicated by the separation of the red and green fluorescent marks. In the absence of gene translocation, the
red and green fluorophores overlap (arrows).
190 K. Jiang et al.Thereafter, the patient’s neoplasm was screened for a new
target, ALK expression by immunohistochemistry, which
showed diffuse, strong staining in the FNAB, lymph nodes,
and globe (Fig. 3A–C). Florescent in situ hybridization (FISH)
of the ocular metastatic lesion demonstrated that he was po-
sitive for EML4-ALK gene translocation (Fig. 3D). Because the
results from a randomized trial suggest that ALK inhibitor,
crizotinib, was superior to other chemotherapies in patients
with ALK rearrangement, his therapy was switched to crizoti-
nib.8 He has remained on this therapy for over 6 months and
remained in stable clinical condition with no evidence of dis-
ease progression at the time of this report.
Discussion
The choroid is the most common location for metastatic
seeding, due in large part to its rich vascular supply.3 These
lesions frequently arise from a silent primary.3 Rarely, a symp-
tomatic choroidal metastasis may be the initial presentation
of a lung neoplasm. One recent meta-analysis approximated
the number of cases presenting in such fashion was 55 cases.
Of these 55 cases, 42% were adenocarcinoma and 22% of the
patients were never-smokers.9
Diagnosis
It can be diagnostically challenging to distinguish a meta-
static lesion from a primary ocular neoplasm and from space-
occupying lesions. Uveal melanoma is the most common pri-
mary intraocular malignancy.10 Six to 10% of patients with
uveal melanoma also have another primary neoplasm.10 It isimportant to obtain a comprehensive history as 66–97% of
patients evaluated for a metastatic choroidal lesion already
would have been diagnosed with a primary neoplasm else-
where.2 Metastases to the choroid are usually nonpigmented
with the exception of metastatic spread from cutaneous mel-
anoma primaries.3,11 Metastatic choroidal lesions are gener-
ally plateau or dome shaped and are often associated with
retinal detachment.3 The presence of serous detachment
and multiple choroidal lesions is more suggestive of
metastases.10,11
Several methods are available for direct characterization
of choroidal lesion, including ultrasonography, fundus auto-
fluorescence (FAF) and FNAB. Ultrasonography differentiates
between choroidal melanoma, metastasis, and hemangioma
with 90% accuracy.12 Metastatic lesions are usually hypere-
chogenic as compared to uveal melanoma on A-mode.12
FAF may be used to aid in the evaluation of the tumor mar-
gin.13 In 17% of patients with uveal metastatic lesions, a pri-
mary neoplastic source may never be found.3 In this
population it would be beneficial to obtain a definitive diag-
nosis through FNAB, with the preservation of visual function
and generally has not been shown to cause seeding along the
needle tract.3Lung cancer
Lung primaries are categorized into small cell and non-
small cell lung carcinoma; approximately 80% of all cases
are non-small cell carcinoma.7,14 Non-small cell carcinomas
are primarily adenocarcinoma, squamous cell carcinoma, or
large cell carcinoma.14 Due to the declining smoking inci-
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carcinoma.5,7,15 Adenocarcinoma can be seen in non-smokers
and is the most common type of lung cancer in women.7,16
Adenocarcinoma usually begins in the periphery of the lung;
it is a slow growing lesion, leading to prolonged latency prior
to diagnosis.16–18 Consequently, these patients are often
diagnosed at an advanced stage with metastatic disease
and a median survival duration of 6–10 months.7
On the other hand, squamous cells carcinoma accounts for
25–31% of NSCLC and is more prevalent in smokers.7 These
lesions are usually central, originate and involve the main
conducting airway, and are symptomatic early into the dis-
ease process.7,18 Large cell carcinoma is a diagnosis of exclu-
sion with no glandular or squamous differentiation making up
approximately 13% of NSCLC and similar to adenocarcinoma
typically occurring in the peripheral regions of the lung.7,18
Small cell carcinoma comprises 20% of all lung cancers7
Although, this type of neoplasm is associated with a rapid
growth rate and early metastasis, small cell carcinoma is gen-
erally highly responsive to chemotherapy and radiother-
apy.7,18 Similar to squamous cell carcinoma, small cell
carcinomas are usually found centrally.7 Smoking is a substan-
tial predisposing risk factor in developing small cell
carcinoma.7Therapy
Early treatment offers the best hope for the preservation
of vision in metastatic uveal cancer. Several approaches exist
to treat these lesions; the utility of each depends upon the
presenting characteristics of the lesion. In general, choroidal
metastases respond favorably to systemic therapy targeted
toward the primary neoplasm.2 However, local therapy is
warranted when there is an enlargement of the lesion, pain,
or when the ocular lesion is the sole metastatic finding. In in-
stances where residual visual function remains, radiotherapy
(brachytherapy or external beam), laser photocoagulation,
and more recently intraocular delivery of bevacizumab may
be offered.2,19 Brachytherapy is most suitable for discrete
small to medium sized lesions, whereas larger lesions close
to the optic nerve and macula are more amenable to external
beam delivery.20 The treatment goal for ocular metastasis is
palliative with the preservation of function and quality of life.
Surgical interventions, such as enucleation, are reserved for
salvage procedures in the treatment of break-through dis-
ease following initial radiation and/or chemotherapy treat-
ment, as occurred with our patient.2,9Special therapeutic considerations
Modern biochemical and genetic characterization of
NSCLC has yielded an insight into the oncogenes involved
in the pathogenesis of these neoplasms. The oncogenes
most commonly associated with NSCLC are EGFR and K-
ras.5,6 Both of these proteins are involved in cellular sur-
vival and proliferation pathways.5,21 Identification of mutant
variants in these genes has stimulated research for the
development of genetically tailored targeted therapy. An
estimated 16.7% of patients with NSCLC have an activating
mutation in EGFR; this rate is higher in patients with ade-
nocarcinoma subtype (49%).22,23 In general, the mutations
occur in exclusion of one another.5,21 Overexpression, dys-regulation, and activated mutations of EGFR result in neo-
plastic proliferation.24 Strong associations exist between
mutations in EGFR and a history of never-smokers, female,
and adenocarcinoma.5,23 Chemotherapeutic drugs have
been formulated to inhibit EGFR activated pathways. The
response rate to these EGFR tyrosine kinase inhibitors
(EGFR TKIs) is strongly dependent on the EGFR mutation
variant. In sensitive mutations such as the exon-19 deletion
and exon-21 L858R point mutation that make up 90% of all
EGFR mutation patients, the response rate to the EGFR
TKIs is approximately 67%.25,26 In randomized trials, these
agents are superior to standard chemotherapy in patients
with EGFR mutation.27
K-ras is a downstream effector of EGFR, and activating
mutations in K-ras are found in 21–43% of individuals with
NSCLC.28 Mutations in K-ras constitutively activated the
downstream cascades leading to neoplastic proliferation.29
Similar to EGFR, K-ras mutations are more likely to be found
in adenocarcinoma.5 However, there is a stronger association
between the presence of K-ras mutation and a past history of
smoking.5 Because K-ras is downstream to EGFR, inhibitors
to EGFR are often insufficient to downregulate K-ras medi-
ated pathways and thus individuals with a K-ras mutation
have a poor prognosis for survival.21,30
Our patient was negative for an EGFR mutation by poly-
merase chain reaction (PCR) analysis. K-ras mutation assess-
ment was not available to our institution. However, he
experienced significant disease progression with formation
of new lesions and an enlargement of existing lesions despite
an initial positive response to cisplatin and vinorelbine. Based
on our patient’s clinical history and histopathological find-
ings, we felt that it was prudent to explore the presence of
a mutation in another less frequent oncogene, ALK. ALK’s
most frequent translocation partner is EML4 in NSCLC, form-
ing an EML4-ALK complex.31 This rearrangement mutation is
present in approximately 5% of NSCLC and is more likely to
occur in adenocarcinoma.8 Lung adenocarcinomas with the
signet ring component and mucinous subtype have
been shown to be strongly associated with ALK transloca-
tion.32–34 An ALK gene rearrangement also is more frequent
in younger individuals and in never-smokers.33 For our pa-
tient, the signet ring morphology was initially revealed in
the choroidal lesion following enucleation. Reassessment of
the original lung FNAB and mediastinal lymph nodes similarly
found signet ring cells (Fig. 2G and H). Given that our patient
fit into all these associative demographics, and that proven
target therapy exists, the patient was tested and found to
be positive for EML4-ALK gene recombination (Fig. 3). Based
on this result, his treatment was switched to crizotinib, which
is currently the only approved ALK tyrosine kinase inhibitor in
North America. For patients with ALK gene rearrangement,
2-year survival rates improved from 12% to 55% with crizoti-
nib treatment.8,35Conclusion
Our case highlights the importance of involving ophthal-
mologists in a collaborative fashion in the ongoing systemic
care of cancer patients, as choroidal metastasis may be the
first sign of a relapse of a known primary malignant neoplasm
or the initial presentation of an unknown primary. For our pa-
tient, the histopathological findings assisted in the identifica-
192 K. Jiang et al.tion of the mutation, which allowed him to receive targeted
and tailored therapy. With the recent stride in personalized
medicine specific histopathological diagnoses are of para-
mount importance to guide targeted therapies for better pa-
tient care management.
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